Meeting Report: The Sixth International Sam Strober Workshop on Clinical Immune Tolerance.

No abstract available

COI Statement

D.B. is a professor in the Department of Internal Medicine at the Johns Hopkins University School of Medicine. D.B. is a private consultant for Medeor Therapeutics and did not engage in research in his capacity as a Johns Hopkins faculty member. D.B. was compensated for the consulting or advising service in income from Medeor Therapeutics. E.F. is a professor in the Department of Oncology at the Johns Hopkins University School of Medicine. E.F. engaged in this research as a private consultant or advisor and not in his capacity as a Johns Hopkins faculty member. E.F. was compensated for the consulting oradvising service in income and equity in ImmunoFree Inc. L.D. is an employee of Quell Therapeutics. M.M.-L. is the founder of Quell Therapuetics and inventor of several patents on Treg therapy. P.R. is the founder of TCbalance pharmaceutical, UKRMP Programme Board Member, scientific advisor of MIGENTRA GmbH, Fraunhofer IBMT, Fabre GmbH, Novo Nordisk, and Sangamo Therapeutic France; and inventor of several patents on Treg therapy. K.S. is an employee of Sangamo Therapeutics. Q.T. is a co-founder, shareholder, and scientific advisor of Sonoma Biotherapeutics. Q.T. is a consultant of Genesis, Qihan Bio, Moderna, Minutia, and Waypoint Bio. Q.T. is an inventor of several patents on Treg therapy. P.T. is co-inventor of patents related to the presented content and stakeholder of the POLTREG venture. The Medical University of Gdansk received payment for the license to the given content. K.U. is a co-founder and shareholder of Juntenbio. The other authors declare no conflicts of interest.

References:

Podestà MA, Binder C, Sellberg F, et al. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro. Am J Transplant. 2020;20:88–100.
Sprangers B, DeWolf S, Savage TM, et al. Origin of enriched regulatory T cells in patients receiving combined kidney-bone marrow transplantation to induce transplantation tolerance. Am J Transplant. 2017;17:2020–2032.
Kawai T, Sachs DH, Sprangers B, et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant. 2014;14:1599–1611.
Morris H, DeWolf S, Robins H, et al. Tracking donor-reactive T cells: evidence for clonal deletion in tolerant kidney transplant patients. Sci Transl Med. 2015;7:272ra10.
Savage TM, Shonts BA, Obradovic A, et al. Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight. 2018;3:e124086.

Article info

Journal issue:

Volume: not provided
Issue: not provided

Doi:

10.1097/TP.0000000000005311

More resources:

Wolters Kluwer

Full Text Sources

Paid

Meeting Report: The Sixth International Sam Strober Workshop on Clinical Immune Tolerance.

No abstract available

COI Statement

References:

Podestà MA, Binder C, Sellberg F, et al. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro. Am J Transplant. 2020;20:88–100.
Sprangers B, DeWolf S, Savage TM, et al. Origin of enriched regulatory T cells in patients receiving combined kidney-bone marrow transplantation to induce transplantation tolerance. Am J Transplant. 2017;17:2020–2032.
Kawai T, Sachs DH, Sprangers B, et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant. 2014;14:1599–1611.
Morris H, DeWolf S, Robins H, et al. Tracking donor-reactive T cells: evidence for clonal deletion in tolerant kidney transplant patients. Sci Transl Med. 2015;7:272ra10.
Savage TM, Shonts BA, Obradovic A, et al. Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight. 2018;3:e124086.